NOORIK BIOPHARMACEUTICALS AG has a total of 18 patent applications. It decreased the IP activity by 60.0%. Its first patent ever was published in 2016. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and measurement are JIANMIN PHARMACEUTICAL GROUPS CORP LTD, GUIZHOU WARMEN PHARMACEUTICAL CO LTD and GUANGZHOU BAIYUNSHAN GUANGHUA PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | United States | 2 | |
#3 | WIPO (World Intellectual Property Organization) | 2 | |
#4 | Australia | 1 | |
#5 | Brazil | 1 | |
#6 | Canada | 1 | |
#7 | Chile | 1 | |
#8 | China | 1 | |
#9 | Hong Kong | 1 | |
#10 | Israel | 1 | |
#11 | Republic of Korea | 1 | |
#12 | Mexico | 1 | |
#13 | Singapore | 1 | |
#14 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Navarro Iker | 15 |
#2 | Khanna Satish | 13 |
#3 | Satish Khanna | 2 |
#4 | Iker Navarro | 2 |
#5 | Brunner Hans | 1 |
Publication | Filing date | Title |
---|---|---|
EP3639827A1 | Use of ambrisentan for the treatment of portal hypertension and cirrhosis | |
EP3235496A1 | Treatment of acute renal failure |